Wed, December 21, 2022
Tue, December 20, 2022
Mon, December 19, 2022
Fri, December 16, 2022
Thu, December 15, 2022
Wed, December 14, 2022

Colin Bristow Upgraded (SRPT) to Strong Buy and Increased Target to $158 on, Dec 16th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. nd-increased-target-to-158-on-dec-16th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Colin Bristow of UBS, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Strong Buy and Increased Target from $100 to $158 on, Dec 16th, 2022.

Colin has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $101 on, Thursday, November 3rd, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022


These are the ratings of the 5 analyists that currently disagree with Colin


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $158 on, Thursday, November 3rd, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022

Publication Contributing Sources